SCHEMBL7910190

SCHEMBL7910190

O=C(CCCCCCn1cc(F)c(=O)[nH]c1=O)NO

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.53
KMT2A Q03164 3/20 0.50
CYP2C9 P11712 2/20 0.49
MAPT P10636 1/20 0.49
CYP1A2 P05177 4/20 0.46
KDM4E B2RXH2 1/20 0.46
GRIA1 P42261 1/20 0.46
GRIA2 P42262 1/20 0.46
GRIA3 P42263 1/20 0.46
GRIA4 P48058 1/20 0.46
GRIK5 Q16478 1/20 0.46
CYP2C19 P33261 3/20 0.45
GAA P10253 1/20 0.45
MEN1 O00255 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
HDAC6 Q9UBN7 7/20 0.44
HDAC3 O15379 5/20 0.44
HDAC1 Q13547 5/20 0.44
HDAC8 Q9BY41 4/20 0.44
HDAC2 Q92769 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14999667 0.86 LMNA (0.56) LMNAKMT2ACYP2C9MAPTCYP1A2
SCHEMBL19103048 0.83 LMNA (0.58) LMNAKMT2ACYP2C9MAPTCYP1A2
SCHEMBL13199364 0.82 LMNA (0.54) LMNAKMT2ACYP2C9MAPTCYP1A2
SCHEMBL7909995 0.81 SQOR (0.53) LMNAKMT2AHDAC6HDAC3HDAC1
SCHEMBL18082002 0.81 SQOR (0.53) LMNAKMT2AHDAC6HDAC3HDAC1
SCHEMBL7910033 0.79 LMNA (0.46) LMNAKMT2ACYP1A2KDM4EGRIA1
SCHEMBL7919650 0.79 LMNA (0.46) LMNAKMT2ACYP1A2KDM4EGRIA1
SCHEMBL12630504 0.79 LMNA (0.59) LMNAKMT2ACYP2C9MAPTCYP1A2
SCHEMBL7917602 0.77 ASAH1 (0.72) LMNACYP3A4CYP2D6MAPK3ASAH1
SCHEMBL7915776 0.77 ASAH1 (0.72) LMNACYP3A4CYP2D6MAPK3ASAH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE46144-E1 Hydroxamic acid derivatives PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) 2016-09-13 US disclosed
US-9096627-B2 Hydroxamic acid derivatives PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) 2015-08-04 US disclosed
US-20140066419-A1 HYDROXAMIC ACID DERIVATIVES PURDUE PHARMACEUTICAL PRODUCTS L.P. (US) 2014-03-06 US disclosed
US-20110269706-A1 Hydroxamic Acid Derivatives NORTHLAKE BIOSCIENCES LLC (US) 2011-11-03 US disclosed
WO-2010085377-A2 HYDROXAMIC ACID DERIVATIVES CRYSTAL BIOPHARMACEUTICAL LLC (US) 2010-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140066419-A1 HYDROXAMIC ACID DERIVATIVES HDAC5, HDAC7, HDAC4 LMNA 2696/4885KMT2A 226/4885CYP2C9 3815/4885
US-20110269706-A1 Hydroxamic Acid Derivatives CD74, HLA-DRB1, HDAC5 LMNA 3497/4885KMT2A 311/4885CYP2C9 2457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.